William Freeman, MD
Ophthalmology · San Diego, CANPI 1518983352
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,880 of the $26,429 with a category attached, or 86.6%. 9 manufacturers reported payments, led by AbbVie at 52.8% of the total. Reporting peaked in 2019 at $12,044 and has fallen 99.8% since, to $23 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $755.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Alcon$8K
- Genentech, Inc.$2K
- F. Hoffmann-la Roche AG$925
- Lensar, Inc.$309
- Lumibird Medical Inc.$232
- plus $309 from 3 others
Across 167 payments — averaging $5880.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$328K
- Janssen Research & Development, LLC$297K
- Apellis Pharmaceuticals, Inc.$190K
- AstraZeneca$53K
- Amgen$47K
- Astellas Pharma Global Development$30K
- plus $37K from 3 others
What the payments were for
- Consulting fees$22,88087%
- Speaking & faculty fees$9253%
- Travel & lodging$1,0074%
- Food & beverage$1,6186%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $13,959 |
| Alcon | 10 | $8,364 |
| Genentech, Inc. | 7 | $2,331 |
| F. Hoffmann-la Roche AG | 1 | $925 |
| Lensar, Inc. | 1 | $309 |
| Lumibird Medical Inc. | 2 | $232 |
| Harrow Eye, LLC | 1 | $212 |
| Amgen | 2 | $54 |
| Ocular Therapeutix, Inc. | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$8,184
- SUSVIMO$1,680
- Lucentis$925
- Non-Covered Product$368
- LENSAR LASER SYSTEM$309
- VEVYE$212
- TANGO OPTIMO$174
- Avastin$119
How this compares
$26,429 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 14 | $1,060 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $720 |
| Ketorolac Tromethamine | 24 | $372 |
| Brimonidine Tartrate | 16 | $127 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.